1. Home
  2. GRC vs NTLA Comparison

GRC vs NTLA Comparison

Compare GRC & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRC
  • NTLA
  • Stock Information
  • Founded
  • GRC 1933
  • NTLA 2014
  • Country
  • GRC United States
  • NTLA United States
  • Employees
  • GRC N/A
  • NTLA N/A
  • Industry
  • GRC Fluid Controls
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • GRC Industrials
  • NTLA Health Care
  • Exchange
  • GRC Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • GRC 1.1B
  • NTLA 1.2B
  • IPO Year
  • GRC N/A
  • NTLA 2016
  • Fundamental
  • Price
  • GRC $42.91
  • NTLA $11.42
  • Analyst Decision
  • GRC
  • NTLA Buy
  • Analyst Count
  • GRC 0
  • NTLA 20
  • Target Price
  • GRC N/A
  • NTLA $32.30
  • AVG Volume (30 Days)
  • GRC 60.5K
  • NTLA 4.0M
  • Earning Date
  • GRC 10-24-2025
  • NTLA 11-06-2025
  • Dividend Yield
  • GRC 1.72%
  • NTLA N/A
  • EPS Growth
  • GRC 51.35
  • NTLA N/A
  • EPS
  • GRC 1.97
  • NTLA N/A
  • Revenue
  • GRC $673,880,000.00
  • NTLA $52,857,000.00
  • Revenue This Year
  • GRC $4.94
  • NTLA $8.32
  • Revenue Next Year
  • GRC $4.47
  • NTLA N/A
  • P/E Ratio
  • GRC $21.77
  • NTLA N/A
  • Revenue Growth
  • GRC 2.60
  • NTLA 14.99
  • 52 Week Low
  • GRC $30.87
  • NTLA $5.90
  • 52 Week High
  • GRC $43.98
  • NTLA $23.76
  • Technical
  • Relative Strength Index (RSI)
  • GRC 54.85
  • NTLA 50.54
  • Support Level
  • GRC $41.98
  • NTLA $10.89
  • Resistance Level
  • GRC $43.98
  • NTLA $12.03
  • Average True Range (ATR)
  • GRC 0.92
  • NTLA 0.63
  • MACD
  • GRC -0.07
  • NTLA 0.02
  • Stochastic Oscillator
  • GRC 49.53
  • NTLA 33.97

About GRC Gorman-Rupp Company (The)

Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of revenue from the United States.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: